EQT Valuation
Is EQBB.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Sales vs. similares
Price-To-Sales vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of EQBB.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: EQBB.F ($25.17) cotiza por encima de nuestra estimación de valor razonable ($24.64)
Muy por debajo del valor justo: EQBB.F cotiza por encima de nuestra estimación del valor razonable.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EQBB.F?
Other financial metrics that can be useful for relative valuation.
| What is EQBB.F's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €34.28b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 16.9x |
| Enterprise Value/EBITDA | 32.3x |
| PEG Ratio | 5.4x |
Price to Sales Ratio vs Peers
How does EQBB.F's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.1x | ||
ARES Ares Management | 7.1x | 16.8% | US$41.5b |
AMP Ameriprise Financial | 2.7x | 4.5% | US$43.6b |
BK Bank of New York Mellon | 2.5x | 2.9% | US$42.7b |
TROW T. Rowe Price Group | 4x | 1.5% | US$26.1b |
EQBB.F EQT | 16.4x | 15.6% | US$395.3b |
Price-To-Sales vs. similares: EQBB.F es caro según su Ratio Price-To-Sales (14x) en comparación con la media de sus homólogos (3.5x).
Price to Earnings Ratio vs Industry
How does EQBB.F's PE Ratio compare vs other companies in the US Capital Markets Industry?
Price-To-Sales vs. Industria: EQBB.F es caro en función de su Ratio Price-To-Sales (14x) en comparación con la media del sector US Capital Markets (2.8x).
Price to Sales Ratio vs Fair Ratio
What is EQBB.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 16.4x |
| Fair PS Ratio | n/a |
PM vs. Ratio Justo: Datos insuficientes para calcular EQBB.F's Price-To-Sales Fair Ratio para el análisis de valoración.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | US$32.00 0% | 10.0% | US$38.53 | US$26.99 | n/a | 11 |
| Mar ’25 | n/a | US$28.77 0% | 11.3% | US$34.94 | US$22.81 | n/a | 12 |
| Feb ’25 | n/a | US$28.08 0% | 11.7% | US$34.29 | US$22.82 | n/a | 12 |
| Jan ’25 | n/a | US$25.91 0% | 10.9% | US$29.08 | US$18.82 | n/a | 12 |
| Dec ’24 | n/a | US$25.58 0% | 13.4% | US$29.30 | US$18.96 | n/a | 12 |
| Nov ’24 | US$17.10 | US$24.85 +45.3% | 12.8% | US$28.45 | US$18.41 | n/a | 13 |
| Oct ’24 | n/a | US$24.61 0% | 12.9% | US$29.91 | US$18.23 | n/a | 13 |
| Sep ’24 | n/a | US$25.03 0% | 14.2% | US$30.19 | US$18.87 | n/a | 14 |
| Aug ’24 | n/a | US$25.50 0% | 14.5% | US$30.53 | US$19.08 | n/a | 14 |
| Jul ’24 | US$19.00 | US$25.44 +33.9% | 15.8% | US$30.61 | US$18.82 | n/a | 13 |
| Jun ’24 | n/a | US$25.39 0% | 16.2% | US$30.32 | US$18.50 | n/a | 13 |
| May ’24 | n/a | US$26.12 0% | 16.6% | US$31.21 | US$19.04 | n/a | 12 |
| Apr ’24 | n/a | US$26.57 0% | 18.6% | US$34.91 | US$18.52 | n/a | 12 |
| Mar ’24 | n/a | US$26.04 0% | 17.9% | US$34.05 | US$18.06 | n/a | 13 |
| Feb ’24 | n/a | US$26.63 0% | 18.3% | US$34.99 | US$18.56 | n/a | 13 |
| Jan ’24 | n/a | US$26.60 0% | 17.4% | US$33.43 | US$18.12 | n/a | 13 |
| Dec ’23 | n/a | US$26.69 0% | 16.1% | US$32.80 | US$17.78 | n/a | 12 |
| Nov ’23 | US$19.00 | US$25.23 +32.8% | 16.3% | US$31.12 | US$17.46 | US$17.10 | 11 |
| Oct ’23 | n/a | US$30.64 0% | 27.0% | US$47.94 | US$16.96 | n/a | 9 |
| Sep ’23 | n/a | US$32.84 0% | 26.7% | US$51.00 | US$18.05 | n/a | 9 |
| Aug ’23 | n/a | US$32.84 0% | 26.7% | US$51.00 | US$18.05 | n/a | 9 |
| Jul ’23 | US$20.00 | US$39.82 +99.1% | 22.6% | US$53.78 | US$25.55 | US$19.00 | 9 |
| Jun ’23 | n/a | US$42.14 0% | 21.5% | US$55.10 | US$26.18 | n/a | 8 |
| May ’23 | n/a | US$45.30 0% | 11.4% | US$54.14 | US$39.51 | n/a | 7 |
| Apr ’23 | n/a | US$49.24 0% | 13.0% | US$57.89 | US$41.17 | n/a | 7 |
Pronóstico de los analistas: El precio objetivo es inferior a 20% superior al precio actual de la acción.